

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-8 (Cancelled).

Claim 9 (Currently amended): The method of ~~Claim 8~~ Claim 17 wherein ~~said infectious disease is selected from pathogenic bacteria, and~~ said alpha-glycosidically linked starch polysaccharide derivative is administered at a minimal inhibitory concentration of from 5 to 60 mg/l.

Claim 10 (Currently amended): The method of ~~Claim 8~~ Claim 17 wherein ~~said infection disease is selected from the group consisting of herpes virus, influenza viruses and combinations thereof, and~~ said alpha-glycosidically linked starch polysaccharide derivative is administered at a minimal inhibitory concentration of from 3 to 50 mg/l.

Claim 11. (Currently amended): The method of ~~Claim 7~~ Claim 17 wherein said alpha-glycosidically linked starch polysaccharide derivative is administered at a dose of 0.1 to 1000 mg/kg of body weight of said patient.

Claim 12 (Currently amended): The method of ~~Claim 7~~ Claim 17 wherein said alpha-glycosidically linked starch polysaccharide derivative has a degree of quaternary ammonium group substitution of from 0.6 to 1.8.


Claim 13 (Currently amended): The method of ~~Claim 7~~ Claim 17 wherein the starch polysaccharide of said alpha-glycosidically linked starch polysaccharide derivative is selected from the group consisting of potato starch, wheat starch, corn starch, rice starch and combinations thereof.

Claim 14 (Currently amended): The method of ~~Claim 7~~ Claim 17 wherein the starch polysaccharide of said alpha-glycosidically linked starch polysaccharide derivative is selected from the group consisting of starches partially hydrolyzed by chemical means, starches partially hydrolyzed by enzymatic means, starches obtained from genetically modified plants and combinations thereof.

Claim 15 (Currently amended): The method of ~~Claim 7~~ Claim 17 wherein said alpha-glycosidically linked starch polysaccharide derivative is administered in a form selected from the group consisting of solutions, suspensions, tablets, capsules, suppositories and combinations thereof.

Claim 16 (Previously Presented): The method of Claim 15 wherein said alpha-glycosidically linked starch polysaccharide derivative is administered by means selected from the group consisting of parenteral administration, intravenous injection, subcutaneous injection, intramuscular injection, intranasal administration and combinations thereof.

Claim 17. (New) A method of inhibiting the growth of pathogenic bacteria or the replication of herpes or influenza viruses in a patient comprising the step of administering to said patient an amount of an alpha-glycosidically linked starch polysaccharide derivative represented by general formula I,



wherein said alpha-glycosidically linked starch polysaccharide derivative has a degree of quaternary ammonium group substitution of from 0.4 to 2.0,

n is 2-4,

R₁ is selected from the group consisting of C₁₋₄ alkyl, benzyl and benzyl substituted with a member selected from the group consisting of C₁₋₃ alkyl, halogen, alkoxy, carbamoyl, alkoxycarbonyl, cyano, dialkylamino and hydrogen,

R₂ and R₃ are each independently selected from the group consisting of C₁₋₄ alkyl, benzyl and benzyl substituted with a member selected from the group consisting of C₁₋₃ alkyl, halogen, alkoxy, carbamoyl, alkoxycarbonyl, cyano and dialkylamino, and

X is an anion selected from the group consisting of halide, hydroxide, sulfate, hydrogen sulfate and carboxylate,

effective to inhibit the growth of said pathogenic bacteria or the replication of said herpes virus or said influenza virus.

Claim 18. (New) The method of claim 17 wherein said pathogenic bacteria are selected from the group consisting of staphylococci and mycobacteria.

Claim 19. (New) The method of claim 17 wherein said pathogenic bacteria are staphylococci.

Claim 20. (New) The method of claim 19 wherein said pathogenic bacteria are *Staphylococcus aureus*.

Claim 21. (New) The method of claim 17 wherein said pathogenic bacteria are mycobacteria.

Claim 22. (New) The method of claim 21 wherein said pathogenic bacteria are *Mycobacterium vaccae*.